Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Consolidated Net Income: 2014-2025

Historic Consolidated Net Income for ImmunityBio (IBRX) over the last 12 years, with Sep 2025 value amounting to -$67.3 million.

  • ImmunityBio's Consolidated Net Income rose 21.55% to -$67.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$348.7 million, marking a year-over-year increase of 40.68%. This contributed to the annual value of -$413.6 million for FY2024, which is 29.15% up from last year.
  • As of Q3 2025, ImmunityBio's Consolidated Net Income stood at -$67.3 million, which was up 27.35% from -$92.6 million recorded in Q2 2025.
  • ImmunityBio's 5-year Consolidated Net Income high stood at -$59.2 million for Q4 2024, and its period low was -$233.4 million during Q4 2023.
  • For the 3-year period, ImmunityBio's Consolidated Net Income averaged around -$117.0 million, with its median value being -$116.6 million (2023).
  • Its Consolidated Net Income has fluctuated over the past 5 years, first slumped by 115.47% in 2023, then skyrocketed by 74.65% in 2024.
  • ImmunityBio's Consolidated Net Income (Quarterly) stood at -$91.6 million in 2021, then fell by 18.32% to -$108.3 million in 2022, then crashed by 115.47% to -$233.4 million in 2023, then soared by 74.65% to -$59.2 million in 2024, then increased by 21.55% to -$67.3 million in 2025.
  • Its last three reported values are -$67.3 million in Q3 2025, -$92.6 million for Q2 2025, and -$129.7 million during Q1 2025.